Chimeric antigen receptor (CAR) T cell therapy has shown promise in hematologic malignancies,
but its application to solid tumors has been challenging 1 , 2 , 3 – 4 . Given the unique …

Potent CD19-directed immunotherapies, such as chimeric antigen receptor T cells (CART)
and blinatumomab, have drastically changed the outcome of patients with relapsed/refractory …

Chimeric antigen receptor T (CAR-T) cell therapy is a new pillar in cancer therapeutics;
however, its application is limited by the associated toxicities. These include cytokine release …

Patients with chemo-refractory acute myeloid leukemia (AML) have a dismal prognosis.
Chimeric antigen receptor T (CART) cell therapy has produced exciting results in CD19+ …

The absence of cancer-restricted surface markers is a major impediment to antigen-specific
immunotherapy using chimeric antigen receptor (CAR) T cells. For example, targeting the …

Chimeric antigen receptor T (CART) cell immunotherapy has been remarkably successful in
treating certain relapsed/refractory hematological cancers. However, CART cell therapy is …

Chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable outcomes in
individuals with hematological malignancies, but its success has been hindered by barriers …

Purpose: Responses to therapy with chimeric antigen receptor T cells recognizing CD19 (CART19,
CTL019) may vary by histology. Mantle cell lymphoma (MCL) represents a B-cell …

Background Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable
activity in patients with refractory or relapsed acute lymphocytic leukaemia. Various anti-…

We and others previously reported potent antileukemia efficacy of CD123-redirected chimeric
antigen receptor (CAR) T cells in preclinical human acute myeloid leukemia (AML) models …